Quattro Financial Advisors LLC Has $3.44 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Quattro Financial Advisors LLC increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 36.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 84,600 shares of the company’s stock after buying an additional 22,500 shares during the quarter. Moderna accounts for approximately 0.9% of Quattro Financial Advisors LLC’s holdings, making the stock its 25th largest holding. Quattro Financial Advisors LLC’s holdings in Moderna were worth $3,439,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp increased its position in shares of Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after acquiring an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC increased its holdings in Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after purchasing an additional 178,115 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after purchasing an additional 906,114 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Moderna by 0.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock valued at $260,023,000 after purchasing an additional 19,819 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Moderna by 6.2% during the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock worth $205,431,000 after buying an additional 178,939 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Moderna Price Performance

Shares of MRNA opened at $32.60 on Friday. The firm has a market capitalization of $12.55 billion, a PE ratio of -5.60 and a beta of 1.59. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The company’s 50-day moving average is $40.22 and its 200-day moving average is $58.87. Moderna, Inc. has a fifty-two week low of $31.94 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the business posted ($1.39) earnings per share. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. Equities analysts forecast that Moderna, Inc. will post -9.18 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on MRNA shares. Argus lowered Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Sanford C. Bernstein started coverage on shares of Moderna in a research report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price objective on the stock. Jefferies Financial Group reduced their target price on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a report on Tuesday, October 15th. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research note on Monday, November 18th. Finally, Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Four equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Moderna has an average rating of “Hold” and a consensus target price of $67.26.

Insider Activity

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is owned by insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.